PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Cytochrome P450 1A1 gene polymorphisms and cervical cancer risk: A systematic review and meta-analysis.

Abstract This meta-analysis aims to examine whether the MspI and Ile462Val polymorphisms of cytochrome P450 1A1 (CYP1A1) are associated with cervical cancer risk.
PMID
Related Publications

CYP1A1 Ile462Val polymorphism contributes to colorectal cancer risk: a meta-analysis.

CYP1A1

The cytochrome P4501A1 gene polymorphisms and endometriosis: a meta-analysis.

Cytochrome P450 1A1 (CYP1A1) gene polymorphisms and ovarian cancer risk: a meta-analysis.

Cytochrome P450 1A1 (CYP1A1) gene polymorphisms and cervical cancer risk: a meta-analysis.

Authors

Mayor MeshTerms
Keywords
Journal Title medicine
Publication Year Start




PMID- 29595663
OWN - NLM
STAT- MEDLINE
DCOM- 20180411
LR  - 20180411
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 97
IP  - 13
DP  - 2018 Mar
TI  - Cytochrome P450 1A1 gene polymorphisms and cervical cancer risk: A systematic
      review and meta-analysis.
PG  - e0210
LID - 10.1097/MD.0000000000010210 [doi]
AB  - OBJECTIVE: This meta-analysis aims to examine whether the MspI and Ile462Val
      polymorphisms of cytochrome P450 1A1 (CYP1A1) are associated with cervical cancer
      risk. METHODS: Eligible case-control studies were identified dated until July
      2017. Pooled odds ratios (ORs) were used to assess the strength of the
      association between the two variants and cervical cancer risk. RESULTS: Thirteen 
      studies were eligible (2148 cases and 2252 controls) concerning MspI polymorphism
      and 8 studies were eligible (1466 cases and 1690 controls) for Ile462Val
      polymorphism. MspI polymorphism seemed to result in cervical cancer risk in any
      genetic model (C allele vs T allele: OR = 1.44, 95% confidence interval [CI] =
      1.16-1.79; heterozygous model: OR = 1.40, 95% CI = 1.08-1.82; homozygous model:
      OR = 2.22, 95% CI = 1.48-3.33, dominant model: OR = 1.50, 95% CI = 1.14-1.98 and 
      recessive model: OR = 1.80, 95% CI = 1.35-2.41); similar significantly increased 
      risk was found among Caucasians and Asians. Ile462Val polymorphism was associated
      with elevated cervical cancer risk (Val allele vs Ile allele: OR = 1.85, 95% CI =
      1.27-2.67; heterozygous model: OR = 1.42, 95% CI = 1.28-1.61; homozygous model:
      OR = 2.94, 95% CI = 1.15-7.54; dominant model: OR = 2.00, 95% CI = 1.33-3.00);
      this finding was replicated upon Caucasian population. CONCLUSION: This
      meta-analysis demonstrated that polymorphisms in MspI and Ile462Val of CYP1A1
      were risk factors for developing cervical cancer.
FAU - Ding, Bo
AU  - Ding B
FAU - Sun, Wei
AU  - Sun W
AD  - Department of Gynecology and Obstetrics, The First Affiliated Hospital of Nanjing
      Medical University, Nanjing, China.
FAU - Han, Suping
AU  - Han S
AD  - Department of Gynecology and Obstetrics, The First Affiliated Hospital of Nanjing
      Medical University, Nanjing, China.
FAU - Cai, Yunlang
AU  - Cai Y
AD  - Department of Gynecology and Obstetrics, Zhongda Hospital, School of Medicine,
      Southeast University.
FAU - Ren, Mulan
AU  - Ren M
AD  - Department of Gynecology and Obstetrics, Zhongda Hospital, School of Medicine,
      Southeast University.
FAU - Shen, Yang
AU  - Shen Y
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - EC 1.14.14.1 (CYP1A1 protein, human)
RN  - EC 1.14.14.1 (Cytochrome P-450 CYP1A1)
SB  - AIM
SB  - IM
MH  - Alleles
MH  - Asian Continental Ancestry Group/genetics
MH  - Cytochrome P-450 CYP1A1/*genetics
MH  - European Continental Ancestry Group/genetics
MH  - Female
MH  - Genetic Predisposition to Disease
MH  - Humans
MH  - Odds Ratio
MH  - Polymorphism, Single Nucleotide
MH  - Risk Factors
MH  - Uterine Cervical Neoplasms/*genetics
EDAT- 2018/03/30 06:00
MHDA- 2018/04/12 06:00
CRDT- 2018/03/30 06:00
PHST- 2018/03/30 06:00 [entrez]
PHST- 2018/03/30 06:00 [pubmed]
PHST- 2018/04/12 06:00 [medline]
AID - 10.1097/MD.0000000000010210 [doi]
AID - 00005792-201803300-00036 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2018 Mar;97(13):e0210. doi: 10.1097/MD.0000000000010210.